Loading...
HomeMy WebLinkAboutAgenda EDAB 110906s ,i►ykruo : S : 3C C,WD&D : 10 vL Economic Development Advisory Board Agenda Thursday: November 9, 2006 at 8:30 a.m. Council Chambers, City Hall 1. Call to Order Ken Kahn, Chair 2. Pledge of Allegiance 3. Roll Call Municipal Services Coordinator 4. Approval of Minutes from October 12, 2006 Members 5. Council Update Mayor Russo 6. Staff Report Dolores Key, Staff Liaison 7. Land Development Petitions a. None 8. Establishment of Next Meeting Topic 9. New Business: Presentation and Open Discussion What's Growing at Scripps Florida. Discoveries and the Business of Science Dr. Claes Wahlestedt, Director of Neuroscience Discovery Dr. Malcolm Leissring, Assistant Professor of Biochem & Neurobiology 10. Next Meeting Date December 14, 2006 11. Public Comment 12. Adjourn Dolores Key, Economic Development and Marketing Director Palm Beach Gardens, Florida Palm Beach Gardens is pleasE Dr. Malcolm Leissring of Scril Discoveries and the Business discuss collaborations between as a case study. For more information: Dolores Key Economic Development & Marketing City of Palm Beach Gardens 10500 North Military Trail Palm Beach Gardens, FL 33410 Direct: 561.799.4136 Email: dkey()obafl.com - The Economic Development Advisory Board of the City of i to announce that special guests Dr. Claes Wahelstedt and ps Florida will co- present What's New at Scripps Florida: )f Science at the November board meeting. The team will scientists, funding challenges & spin -offs utilizing a single lab Topic: What's New at Scripps Florida: Discoveries and the Business of Science Guests: Dr. Claes Wahelstedt & Dr. Malcolm Leissring When: November 9, 9006 — Thursday 8:30 am Where: Council Chambers 10500 North Military Trail Palm Beach Gardens, Florida Public Encouraged to Attend! Claes Wahlestedt, Ph.D. Professor — Department of Biochemistry & Director of Neuroscience Discover Dr. Wahelstedt earned his M.D. and Ph.D. degrees from the University of Lund (Sweden) in 1984 and 1987 respectively. After post - doctoral training at Kyoto University, Japan, and at Georgetown University, Washington, DC, he took a position as Assistant Professor at the Department of Neurology and Neuroscience, Cornell University Medical College in New York City. He then joined the pharmaceutical industry and from 1993 to 1997 Dr. Wahlestedt served as (founding) Director of Astra- Zeneca Research Center in Montreal, Canada. With a focus on drug discovery for brain disorders and for pain, he grew this Center to over 100 scientists. In Montreal, he was also an Adjunct Professor at McGill University. In 1997 Dr. Wahlestedt was appointed Professor and started the Center for Genomics and Bioinformatics at the Karolinska Institute in Stockholm (Sweden) and helped recruit some 150 scientists over the following several years. This Center was established in close collaboration with Pharmacia &Upjohn (later Pharmacia Corp. and Pfizer Inc.). Since 2004, Dr. Wahelstedt has been an Adjunct Chief Scientist at the Japanese National Research Institute, RIKEN. In 2005, he joined Scripps Florida as Professor and Director of the Neuroscience Discovery (CNS Disease) Program. In addition to the drug discovery work, his current research focuses on basic aspects of genomics and genetics. Dr. Wahlestedt accompanied Governor Jeb Bush on a recent recruiting trip to the United Kingdom and was a guest facilitator and lecturer at the first Florida Cured Summit as created by the Florida Legislature. In addition to his experience from over a decade as a senior manager in the pharmaceutical industry, Prof. Wahlestedt has served on boards of a number of smaller biotech companies. He has published over 150 peer reviewed original scientific articles as well as many review articles and patents. Malcolm Leissring, Ph.D. Assistant Professor, Biochem & Neurobiology Dr. Malcolm Leissring, currently the lead Alzheimer's disease researcher at Scripps Florida, began his research career at UC Berkeley in 1988 investigating fundamental ft 4 mechanisms of learning and memory formation. After receiving a Masters degree from San Francisco State University, Dr. Leissring sought to apply this knowledge to Alzheimer's disease, t the leading memory disorder in humans. To that end, he joined the laboratory of Dr. Frank LaFerla at UC Irvine, who has developed one of the most successful and widely studied Alzheimer's mouse models in use today. After earning his Ph.D. from UC Irvine, Dr. Leissring conducted his post - doctoral research in the laboratory of Dr. Dennis Selkoe at Harvard Medical School, a world- renowned Alzheimer's disease researcher. In Dr. Selkoe's laboratory, Dr. Leissring conducted a seminal study showing that Alzheimer's disease could be completely prevented in mice by activating of a special class of enzymes that can break down the beta - amyloid peptide, the primary constituent of the plaques that litter the brains of Alzheimer's disease patients. This novel finding has unveiled a host of novel drug targets that his lab is pursuing at Scripps Florida. With over 30% of land -mass dedicated to green space, recreation programs tailored for residents of all ages, and a pro- active business climate that embraces innovation - Palm Beach Gardens is a signature city which celebrates quality -of -life by fostering an environment of excellence. For more information about the City of Palm Beach Gardens, please visit www.,pb_qfl.com • A new approach to developing treatments for Alzheimer's disease: progress and possible spin -offs Malcolm A. Leissring, Ph.D. S C R I P P S TLO t{ 11) 1 Tow Scxrrr•s ResKANcio I- wrrri,•rv. • C, ALZHEIMER'S DISEASE IN 2006 Most common cause of dementia Affects 3 -4 million Americans, 15 -20 million worldwide Accounts for > $100 billion in annual costs in the U.S. alone No cure or effective treatment _ .. _� "A;ysk;,,ROUdelw • 1 "M composed of amyloid P- protein (AP) Alzheimer's Disease TANGLES composed of hype rphosphorylated tau Extensive neuronal cell death P-amyloid (AP) • primary constituent of senile plaques • a short protein fragment (37 to 43 amino acids) • very "sticky ", especially the longer forms produced naturally by all of us • people with inherited forms of Alzheimer's produce too much P- amyloid B- amyloid precursor protein (APR) Life history of amyloid 0- protein (AD) T H E O R Y AND ■ A C K O R O U N D B- amyloid precursor protein (APP) �c ftwo B- secretase C�+i�wi�1 Life history w of amyloid B- protein (AD) B- amyloid precursor protein (APP) :lElrrri.�M B- secretase wwl :'L�ll1 Life history y- secretase No of amyloid amw.11 ;*w 0- protein (AD) T H E O A B- secretase B- amyloid precursor protein (APP) Life history y-secretase of amyloid 0- protein (AB) aggregation r B- amyloid precursor protein (APP) B- secretase Life history y- secretase of amyloid '" = f3- protein aggregation © �o degradatproteion lytic h 0 I _:.:., V A7i0 6 ACKGR0 1174,n Life history of amyloid B- protein it V proteolytic degradation B- amyloid precursor protein (APP) B- secretase y- secretase aggregation AB "clearance' W-A A Ow / p roteoI is i degrad to APP /presenilin normal brain "sporadic" mutations Alzheimer's disease Ap- degrading proteases • Insulin- degrading enzyme (IDE) Neprilysin (NEP) - endothelin- converting enzyme 1 and 2 Others — Plasmin t -PA u -PA — Cathepsin D — Angiotensin- converting enzyme — MMP -2, MMP -9 "unclogging the drain" can completely prevent Alzheimer's disease in mice No treatment + A[I- degrading protease Leissring et at., Neuron 2003 Peripheral AR degradation hypothesis - Peripheral and central pools of AR are in dynamic equilibrium - Peripheral Ali- binding compounds reduce brain Ali - Proteases have advantages that may render them ideal therapeutics catalytic irreversible This means Alzheimer's can be treated without drugs ever entering the brain ! Ap- degrading proteases • Insulin- degrading enzyme (IDE) • Neprilysin (NEP) • endothelin- converting enzyme 1 and 2 Others — Plasmin t -PA u -PA — Cathepsin D — Angiotensin- converting enzyme — MMP -2, MMP -9 • W Ut '9 0c 1,b :006 &k10.w38/.r ,0516) LETTERS Structures of human insulin - degrading enzyme reveal a new substrate recognition mechanism Yuequan Shen'. Andrzej Joachimiak=. Marsha Rich Rosner' S Wei -Jen Tang' Val Mx X% lay 2006 NEWS & VIEWS STRUCTURAL BIOLOGY Enzyme target to latch on to Malcolm A Lelss• ng and Dennis J it • • closed Normal IDE open 0 • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • closed IDE + drug open • • • • • • • • • • • • • • • • 0 • • • • • • • • • • • • • • • • 0 • • • • • • . . i • We have discovered small molecules that activate insulin- degrading enzyme 350 .Y 300 250 T , 200 U -2 150 100 - i 50 0 1 10 100 1000 [Activator 1] (uM) • I-) • The "spin- off ": IDE inhibitors • a badly needed tool for investigating IDE's role in Alzheimer's • currently only very poor inhibitors are available • may hold therapeutic potential in diabetes... ...and wound healing ...and chicken pox / shingles ...and life -span extension? • Mice lacking IDE have elevated insulin levels 2.0 _ 1.5 NN to J E CM 1.0 �c a� cn 0.5 0.0 IDE +/+ IDE -/- * p < 0.01 • I IDE inhibitors enhance effects of insulin 100 K 80 u< 3 GO m � J 4 2 �0 u W ".AI.L E 0 10 r - -� L'111B170N 0 0 1 ) 4 0 1 L I HOURS AFTER L'7UUN Mirsky, Science 1955 J A known inhibitor of IDE (bacitracin) promotes wound healing tNKiiPa; [oaqtart6s9 NEO GRIN we have designed inhibitors that are 1,000,000 times more potent 14 • IDE inhibitors increase the action of insulin within cells insulin: + - + - IDE inhib: - - + + phospho -p175 ► IRS -1 /2 Insulin Degrading Enzyme Is a Cellular Receptor Mediating Varicella- Zoster Virus Infection and Cell -to -Cell Spread O..g.- L,' My A. Ali,' -d J0,.y I. Cohen' ' Medical V rda0y Sm%w. Labo, 0 d U-- IMe — CEeese> A.Liorol Ira14UM d N Z, BMY d& MD. 20892 USA 'Cmhd: jC~ Wi.Wd,V00v DOI 10.10164- 1- NM06046 IDE inhibitors prevent chicken pox and shingles ! i�, • Inhibition of IDE in worms enhances lifespan ! Bacteria Mean lifespan Vector (pAD12) 29 ds daf- -16 (pAD43) 15 ds F44E7.4 36 ds CO2G6.1 34 ds 0)2G6 2 ;l ds Y7005C.1 35 ds • • r� • a Thank you !!!! ,� ... .............- Jimmy Zhao Kendall Nettles Peter Hodder Lilly Li John Bruning Tim Spicer Anna Leech Jeff Habel Louis Scampavia Malwina Huzarska Maria Rodriguez John Hogenesch Charles Weissmann Nagi Ayad Josephine Harada Vittorio Verzillo Scott Simanski Trey Sato Tony Smith Amanda Kuber James Tam Mark Gosink Yi -An Lu Jennifer Busby Valerie Cavett Mike Chalmers Emily Wu and staff Jeremiah Tipton Pat Griffin Tammy Richmond Candy Walker Stephan Schurer Patty Doherty AJ Brockman The Unforgettable Fund • 17 • Scripps and its Spin -Offs: The Business of Science Palm Beach Gardens, Nov. 9, 2006 Claes Wahlestedt, M.D. Ph.D. Professor and Director (Neuroscience Discovery) The Scripps Research Institute - Florida The Scripps Research Institute: Mission Perform high impact basic biomedical research • Improve the human condition by fostering translation of scientific discoveries into useful products Enable the highest quality graduate scientific education and post graduate scientific training • 1 • Building a biotech spin -off company: it takes a campus University or Research Institute + favorable environment: Mass. Inst. Technol. (MIT) in Cambridge, MA Natl. Inst. Health (NIH) in Bethesda, MD Stanford in Palo Alto, CA Univ. Calif. San Diego / Scripps / Salk in La Jolla, CA Scripps in Jupiter, FL C7 Scripps Flondc -1 Status 11 /06) Florida Atlantic Universi y, Jupiter Campus Phase I (Feb, 2005) 41,000 sq ft lab space Trailers (3) 01 190 people: 152 scientists including 25 faculty Phase 11 (Sep, 2006) 33,000 sq ft lab space Additional trailers (2) 111111110 FUN Phase III (early 2009) 310,000 sq ft lab space 40,000 sq ft admin space • 2 • Building a biotech spin -off company : types of inventions • Service: fast, low risk but low return • Diagnostic tools: medium risk, return • Drug: slow, high risk but high return • Medical Devices: comparable to diagnostic tool • Biotech's Global -ness Begins Day 1 • Science /technology • Intellectual property /patents • People • Capital • Markets — diseases know no borders • Even the smallest biotech is a global player rI 3 • 0 C7 Major Biotech Initiatives Not Just in US /Europe, but also... • Japan • China • Russia /Eastern Eur. • Cuba • India • Brazil • Malaysia • Thailand • Korea • Singapore • Israel • Bahrain /Dubai /Middle East • South Africa • Canada • Australia /New Zealand Top 5 US Pharma vs. Biotech Market Cap Sea4 3 H S 'ta41 t(IOt tlXl:f t44e 1aa4 Sm4 Top US Pharma Se4o 35W Sean Total Biotech Market Cap S4a4 $ tan 5104 • • Building a biotech sp�- -off company: sources of seed - financing • Family and Friends • Business "Angels" • Federal grants • Venture capital investors • Public seed funding 0 5 Building a biotech spin -off industry: a few recent year 2006 numbers LICENSOR LICENSEE UP -FRONT MILESTONES (up to) Regeneron Bayer $75M $275M Intermune Roche $60M $420M Infinity Medimmune $70M $430M ChemoCentryx Glaxo $63.5M $1,500M Actelion Roche $75M $555M Human Genome Novartis $45M $507.5M • Building a biotech sp�- -off company: sources of seed - financing • Family and Friends • Business "Angels" • Federal grants • Venture capital investors • Public seed funding 0 5 • Feel Good /Feel Better Drugs •Lipitor Lowers Cholesterol Pfizer •Propecia Male Pattern Baldness Merck •Renova Wrinkle Remover JNJ •Celebra Arthritis Pain Pfizer -Sonata Insomnia Wyeth •Evista Osteoporosis Eli Lilly •Detrol Incontinence Pfizer •Viagra Male Impotence Pfizer • Chronic Disease 125 million Americans have 1 or more chronic conditions (e.g. congestive heart failure, diabetes, Mzheimer's) • Chronic diseases account for 75% of all health care expenditures • Current costs for chronic diseases is approaching $1 trillion • These expenditures are not delivering what is possible 0 6 • Aging ... Is it a disease? • About 1.4 million Americans are in their 90s, and another 64,000 are 100 years old or older • Baby boomers represent 30% of the total US population • Per person, seniors consume about five times the drugs of their working -age counterparts • By 2030, 20% of US population will be over 65 years of age • 0 7 • Big "new" markets •Alzheimer's /memory • Anti -aging • Obesity /diabetes • Wellness (preventative /predictive cure) L NOD ELSTIFTELSEN 11c .Nobel Foundation 2006 Nobel Conference: "The Functional RNA World" (C. Wahlestedt, Chair) Andy Fire & Craig Mello, Physiology or Medicine, 2006 Roger Kornberg, Chemistry, 2006 • • • What we eat plays a big part in how long we'll live, and how healthy we'll be in the process VLEDICALBULLETIN i Abh �: w 9 • Human Diversity 0 Genome variation Difference • —0.1% Difference 10 • The genetic basis for the variation in health among human beings 0 Alzheimer's, depression, schizophrenia, autism, addict Genes: 60 -s0% DNA �/1, i Mi17/ddi a N II .1 Cell 1 �1 , -� Mali PRDO • of t tt r ►' Nuclear N maw /t it RNA a Aembrane Environment: 20 -40% 11 • Future: Tailor Made Medicines "40000 0 12 Pfice tag from Alzheimer's disease will skyrocket over the next 25 years Page 1 of 1 Materials 0 News- Medical.Net Nanotechnology r network Building • Home Page Price tag from Alzheimer's disease will skyrocket over the next 25 years Medical Studies[Trials Published: Friday, 17- Mar -2006 Printer Friendly TM Email to a Friend A new report concludes the price tag from Alzheimer's disease will skyrocket over the next 25 years, particularly in Florida, home to the nation's fastest - growing over- 65 and over -85 populations. The study prompted a new coalition of researchers, health care providers, business leaders and senior advocates to call for an "all -out push" to find a cure. The new economic study released today documents a near doubling of Florida's costs due to Alzheimer's in the next 25 years, spurred in large part by the aging of Florida's population. An estimated one -tenth of all Alzheimer's patients live in Florida. While Florida's case is the most dramatic, the rest of the nation will experience growing •costs, as well. The report was commissioned in conjunction with the 100th anniversary of the discovery of Alzheimer's disease. Alzheimer's disease also takes a toll on businesses: Nationally, businesses spend at least $25 billion each year on health care for people with Alzheimer's and rack up $37 billion in lost productivity due to employees with caregiving responsibilities. "America moves forward when its citizens and leaders set bold agendas and commit ourselves to working together to accomplish ambitious goals. That's how we put a man on the moon," said Dr. Huntington Potter, Ph.D., chief executive officer of the Byrd Alzheimer's Institute. "It's time to make eliminating the scourge of Alzheimer's a pressing, national priority." Potter and fellow researcher Malcolm Leissring, Ph.D., who heads up the Alzheimer's research lab at The Scripps Research Institute in Jupiter, said a cure for Alzheimer's is within reach and additional research dollars can hasten the timeline for critical discoveries. "Policymakers and the public need to know about the tremendous progress we've made toward identifying causes, prevention strategies and even a cure for Alzheimer's disease," Leissring said. "Investment in Alzheimer's research is as promising as it is pressing." That progress includes identifying genes that correlate with Alzheimer's incidence, which ultimately may lead scientists to new treatments and diagnoses. Byrd Institute researchers also have achieved stunning results in regenerating neurons, which may restore brain functioning in Alzheimer's victims and may also offer significant hope to victims of Lou Gehrig's disease and spinal cord injuries. http : / /www.curealzheiniersnow.org/ • http: / /www.news- medica].net /print article. asp?id =16704 11/6/2006